Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

11/12/24 4:59:47 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $OCGN alert in real time by email

SC 13G/A 1 UnitedStates_13G__OcugenIncU.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Ocugen Inc (Title of Class of Securities) Common Stock (CUSIP Number) 67577C105 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 67577C105 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 483,183 (7) Sole dispositive power 16,374,387 (8) Shared dispositive power 574,632 (9) Aggregate amount beneficially owned by each reporting person 16,949,019 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.88% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Ocugen Inc Item 1(b) Address of issuer's principal executive offices: 11 Great Valley Parkway Malvern, PA 19355 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 67577C105 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 16,949,019 (b) Percent of class: 5.88% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 16,949,019 (b) Percent of class: 5.88% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 483,183 (iii) Sole power to dispose or to direct the disposition of: 16,374,387 (iv) Shared power to dispose or to direct the disposition of: 574,632 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

Get the next $OCGN alert in real time by email

Recent Analyst Ratings for

$OCGN

Date	Price Target	Rating	Analyst
3/17/2026	$12.00	Buy	Canaccord Genuity
3/11/2026	$10.00	Outperform	Oppenheimer
10/15/2024	$4.00	Buy	Maxim Group
3/1/2023	$3.50	Neutral → Buy	Chardan Capital Markets
8/23/2022	$5.00	Buy	Mizuho
6/15/2022	$8.00	Buy	ROTH Capital
6/2/2022	$4.50	Overweight	Cantor Fitzgerald
2/28/2022	$10.00 → $8.00	Buy	HC Wainwright & Co.

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

11/12/24 4:59:47 PM ET

$OCGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $OCGN alert in real time by email

Recent Analyst Ratings for

$OCGN

Date	Price Target	Rating	Analyst
3/17/2026	$12.00	Buy	Canaccord Genuity
3/11/2026	$10.00	Outperform	Oppenheimer
10/15/2024	$4.00	Buy	Maxim Group
3/1/2023	$3.50	Neutral → Buy	Chardan Capital Markets
8/23/2022	$5.00	Buy	Mizuho
6/15/2022	$8.00	Buy	ROTH Capital
6/2/2022	$4.50	Overweight	Cantor Fitzgerald
2/28/2022	$10.00 → $8.00	Buy	HC Wainwright & Co.

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OCGN

Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OCGN

$OCGN
SEC Filings

Ocugen Inc. filed SEC Form 8-K: Leadership Update

Ocugen Inc. filed SEC Form 8-K: Leadership Update, Other Events

Ocugen Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

$OCGN
Insider Trading

SEC Form 4 filed by Zhang Junge

New insider Johnson-Greene Treerita Essalima claimed ownership of 500,350 shares (SEC Form 3)

Chief Executive Officer Musunuri Shankar was granted 3,123,201 shares, increasing direct ownership by 170% to 4,955,924 units (SEC Form 4)

$OCGN
Press Releases

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

$OCGN
Insider Purchases

Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

$OCGN
Analyst Ratings

Canaccord Genuity initiated coverage on Ocugen with a new price target

Oppenheimer initiated coverage on Ocugen with a new price target

Maxim Group initiated coverage on Ocugen with a new price target

$OCGN
Leadership Updates

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

$OCGN
Large Ownership Changes